Dark Matter Technologies announces comprehensive eClosing integration for its NOVA LOS platform
- Powered by Wolters Kluwer, eClose solution streamlines mortgage closings, supports cost savings and facilitates the compliant transfer and sale of digital loans -
JACKSONVILLE, Fla., June 3, 2025 (SEND2PRESS NEWSWIRE) — Dark Matter Technologies (Dark Matter®), an innovative leader in mortgage technology, announced today that the NOVA loan origination system (LOS) platform now features a comprehensive integration to the eClosing capabilities powered by the Wolters Kluwer eOriginal® ClosingCenter. Designed to improve the mortgage closing process, eClose will help lenders reduce time-to-close, realize cost savings and provide a better borrower experience while also enabling secondary market activities.
The eClose functionality enables users to seamlessly execute the full spectrum of eClosing options: hybrid eClosings, In-Person Electronic Notarization (IPEN) closings and digital 'Remote Online Notarization' (RON) closings. This allows lenders to evolve their eClosing strategy over time and provide borrowers with flexible closing options.
The eOriginal® ClosingCenter solution allows NOVA clients to securely eSign and create eNotes, then deposit loan documents into the eOriginal eAsset® Management system for secondary market activities. This allows for compliant transfer and sale of digital lending assets. eSigned documents in the eVault are legally compliant and maintain the highest level of legal enforceability throughout a digital loan's lifecycle. This solution simplifies digital lending, reducing paperwork, ensuring compliance and speeding up loan cycles.
'With this capability, lenders can deliver an entirely new level of convenience and efficiency,' said Sean Dugan, the chief executive officer of Dark Matter Technologies. 'This saves time and money for lenders while allowing them to engage in secondary market activities and gives homebuyers the convenience of faster closings at the time and place of their choosing.'
Dark Matter Technologies added the NOVA LOS to its product line-up in 2024 as part of a dual-product strategy alongside the Empower® LOS to provide innovative solutions and consultative services for credit unions, IMBs and small to midsize banks. The NOVA LOS provides a reliable, cost-effective solution with minimal administrative and supports retail, wholesale and correspondent lending as well as a wide range of mortgage products.
'By integrating flexible, modern eClosing options to NOVA LOS, Dark Matter is putting lenders on a fast track to a fully digital future,' said Shreya Shankar, the vice president of partnerships at Wolters Kluwer Financial & Corporate Compliance. 'We are thrilled to collaborate with Dark Matter to help NOVA LOS users enhance borrower satisfaction, increase revenue, streamline operational efficiency and unlock the potential of the secondary market through seamless eClosings.'
About Dark Matter Technologies:
Operating with the nimble nature of a startup and the disciplined maturity of one of the industry's leading providers, Dark Matter Technologies delivers powerful technology with unparalleled automation and relentless innovation to leading mortgage lenders, servicers and companies nationwide. For more information, visit https://www.dmatter.com/.
X: @dmattertech @NOVALOS @Wolters_Kluwer #fintech #mortgage
Logo link for media: https://dmatter.com/wp-content/uploads/dark-matter-tech-logo.svg
NEWS SOURCE: Dark Matter Technologies
###
MEDIA ONLY CONTACT:
(not for publication online or in print)
Elizabeth Schroeder
Depth for Dark Matter Technologies
(209) 774-6555
[email protected]
###
Keywords: Mortgage, Wolters Kluwer, eClose solution, mortgage closings, fintech, Dark Matter Technologies, loan origination system, JACKSONVILLE, Fla.
This press release was issued on behalf of the news source (Dark Matter Technologies) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P126692 APNF0325A
To view the original version, visit: https://www.send2press.com/wire/dark-matter-technologies-announces-comprehensive-eclosing-integration-for-its-nova-los-platform/
© 2025 Send2Press® Newswire, a press release distribution service, Calif., USA.
RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT.
Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice ® fully human antibody platform family. It underscores the continued advancement of Biocytogen's comprehensive global patent strategy and highlights the innovation and international recognition of the company's proprietary technologies. RenMab™ mice are a core member of Biocytogen's independently developed RenMice ® fully human antibody discovery platform family. Using Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE ®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts. As a result, RenMab mice have the full repertoire of human antibody heavy chain VDJ and light chain VJ genes. It retains the ability to mount robust immune responses against diverse antigens, comparable to wild-type mice, and can generate fully human antibodies with native-like diversity, significantly improving the efficiency and success rate of discovering high-potential therapeutic candidates. Importantly, antibodies derived from RenMab mice require no additional humanization, effectively minimizing immunogenicity risks and streamlining the antibody drug development process. With distinct advantages in discovering fully human antibodies and TCRs with low immunogenicity, high diversity, favorable affinity, and excellent physicochemical properties, Biocytogen's RenMice platform series (RenMab™/RenLite ® /RenNano ® /RenTCR-mimic™/RenTCR™) has gained widespread recognition in the global biotech and biopharmaceutical industry. Licensing agreements have been established with 20+ companies, including Merck KGaA, Darmstadt, Germany, Janssen/ Johnson & Johnson, and BeiGene. Leveraging the RenMice platform, the RenBiologics™ program has generated over 1,000,000 fully human antibody sequences and numerous high-potential preclinical candidates against more than 1,000 therapeutic targets. As of December 31, 2024, approximately 200 agreements encompassing therapeutic antibody co-development, out-licensing, and asset transfers have been executed, highlighting the RenMice platform's strong global competitiveness and significant commercial value. With its sustained independent research and cutting-edge technological innovation capabilities, Biocytogen has been actively advancing its global patent portfolio and key technology protections for the RenMice ® platform. To date, the RenMice platform has secured patent grants in nearly 10 countries, including the U.S., China, and Japan, while nearly 40 patent applications are under examination across 15 countries and regions. With the steady progress of the global patent strategy, additional patent grants are anticipated in the near term. This strong intellectual property protection framework will continue to deliver reliable assurance to Biocytogen's partners worldwide. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit
Yahoo
2 hours ago
- Yahoo
VSI Leads Groundbreaking National Study Showing Holistic Recovery Program Improves Spine Surgery Outcomes
Study of 50,000+ patients shows Enhanced Surgical Recovery protocol leads to faster healing, reduced opioid use, and fewer re-admissions after spinal fusion surgery RESTON, Va., June 5, 2025 /PRNewswire/ -- Spine surgeons at VSI® have led one of the largest nationwide studies of its kind, revealing that a more comprehensive, patient-centered approach to spine surgery recovery can lead to faster healing, reduced pain, and fewer complications. The research, which analyzed outcomes from more than 50,000 thoracolumbar spinal fusion cases by 1,352 surgeons at 138 centers across the US, validates the effectiveness of an Enhanced Surgical Recovery (ESR) program developed and implemented by VSI's expert team. This research was conducted in collaboration with the HCA Healthcare Spine Research Consortium. "Spine surgery has come a long way, but recovery is where the real transformation happens," explains lead author Dr. Christopher Good, MD, a spine surgeon and the president and CEO of VSI. "With Enhanced Surgical Recovery, we're not just performing successful surgeries; we're empowering patients to heal faster, use less medication, and return to their lives with fewer setbacks. This research proves that when we treat the whole patient, we achieve dramatically better outcomes." A New Standard in Spine Surgery RecoveryThe evidence-based Enhanced Surgical Recovery (ESR) program is a multiphase protocol designed to optimize patient outcomes before, during, and after spinal fusion surgery. It includes pre-surgical education, opioid-sparing anesthesia techniques, and early initiation of mobility and nutrition to accelerate healing and reduce dependence on medications. "This movement is about reimagining what it means to recover from spine surgery," spine surgeon and co-author Dr. Ehsan Jazini says. "We're proving that with the right preparation and post-op care, patients can recover faster, get back to life, and avoid unnecessary complications." Key Findings from the Research Study: Less Pain Medication: Patients in the ESR program used an average of 8 fewer morphine-equivalent milligrams per day. Shorter Hospital Stays: The average patient stay was reduced by nearly half a day (86 hours vs. 98 hours). Fewer Re-admissions: ESR patients had a significantly lower 30-day re-admission rate (5.8% vs. 6.7%), and for single-level surgeries, re-admissions dropped from 5.6% to just 4.2%. About Thoracolumbar Spinal Fusion Surgery:Thoracolumbar spinal fusion is used to stabilize the spine by permanently joining two or more vertebrae in the mid-to-lower back. It is commonly used to treat: Degenerative disc disease Scoliosis Spinal fractures Spondylolisthesis Spinal stenosis Tumors or infections of the spine This surgical procedure can significantly reduce pain, correct spinal deformities, and prevent further deterioration, but recovery is key to long-term success. About VSI:VSI (formerly Virginia Spine Institute), based in Reston, VA, is a nationally recognized leader in spinal healthcare, offering advanced surgical and non-surgical solutions tailored to each patient. With over 30 years of experience and more than 100,000 patients treated, VSI delivers proven outcomes through its personalized, concierge-style approach. For more resources and spine support, listen to the Get Back To Your Life® podcast on iTunes, Spotify, and YouTube. View original content to download multimedia: SOURCE VSI
Yahoo
2 hours ago
- Yahoo
Share Buyback Transaction Details May 29 – June 4, 2025
PRESS RELEASE Share Buyback Transaction Details May 29 – June 4, 2025 Alphen aan den Rijn – June 5, 2025 - Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 225,452 of its own ordinary shares in the period from May 29, 2025, up to and including June 4, 2025, for €35.2 million and at an average share price of €155.93. These repurchases are part of the share buyback program announced on February 26, 2025, under which we intend to repurchase shares for up to € 1 billion during 2025. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2025 Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€) 2025 to date 2,750,306 427.5 155.43 For the period starting May 8, 2025, up to and including July 28, 2025, we have engaged third parties to execute €350 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company's Articles of Association. Shares repurchased are added to and held as treasury shares and will be used for capital reduction purposes through share cancelation. Further information is available on our website: Download the share buyback transactions excel sheet for detailed individual transaction information. Weekly reports on the progress of our share repurchases. Overview of share buyback programs. For more information about Wolters Kluwer, please visit: ### About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,600 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50 and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram. Media Investors/Analysts Stefan Kloet Meg Geldens Associate Director Vice President Global Communications Investor Relations press@ ir@ Forward-looking Statements and Other Important Legal InformationThis report contains forward-looking statements. These statements may be identified by words such as 'expect', 'should', 'could', 'shall' and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU). Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries. Attachment 2025.06.05 Share Buyback Transactions May 29 - Jun 4 2025Sign in to access your portfolio
